Evaluation of potential novel biomarkers for feline hypertrophic cardiomyopathy

IF 2.2 3区农林科学 Q1 VETERINARY SCIENCES

Research in veterinary science Pub Date : 2024-10-09 DOI:10.1016/j.rvsc.2024.105430

Andrew Chong , Jessica Joshua , Shari Raheb , Ananda Pires , Michelle Colpitts , Jeff L. Caswell , Sonja Fonfara

{"title":"Evaluation of potential novel biomarkers for feline hypertrophic cardiomyopathy","authors":"Andrew Chong , Jessica Joshua , Shari Raheb , Ananda Pires , Michelle Colpitts , Jeff L. Caswell , Sonja Fonfara","doi":"10.1016/j.rvsc.2024.105430","DOIUrl":null,"url":null,"abstract":"<div><div>Hypertrophic cardiomyopathy (HCM) is the most common cardiomyopathy in cats. The diagnosis can be difficult, requiring advanced echocardiographic skills. Additionally, circulating biomarkers (N-terminal pro-B type natriuretic peptide and cardiac troponin I) have several limitations when used for HCM screening. In previous work, we identified interleukin 18 (IL-18), insulin-like growth factor binding protein 2 (IGFBP-2), brain-type glycogen phosphorylase B (PYGB), and WNT Family Member 5 A (WNT5A) as myocardial genes that show significant differential expression between cats with HCM and healthy cats. The products of these genes are released into the circulation, and we hypothesized that IL-18, IGFBP-2, PYGB, and WNT5A serum RNA and protein concentrations differ between healthy cats, cats with subclinical HCM, and those with HCM and congestive heart failure (HCM + CHF).</div><div>Reverse transcriptase quantitative polymerase chain reaction (RTqPCR) and enzyme-linked immunosorbent assay (ELISA) were applied to evaluate gene and protein expression, respectively, in the serum of eight healthy controls, eight cats with subclinical HCM, and six cats with HCM + CHF. Serum IGFBP-2 RNA concentrations were significantly different among groups and were highest in cats with subclinical HCM. Compared to healthy controls, serum IL-18 and WNT5A gene expression were significantly higher in cats with HCM + CHF, and WNT5A was higher in cats with subclinical HCM. No differences were observed for PYGB.</div><div>These results indicate that further investigation via large scale clinical studies for IGFBP-2, WNT5A, and IL-18 may be valuable in diagnosing and staging feline HCM.</div></div>","PeriodicalId":21083,"journal":{"name":"Research in veterinary science","volume":"180 ","pages":"Article 105430"},"PeriodicalIF":2.2000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research in veterinary science","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0034528824002972","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common cardiomyopathy in cats. The diagnosis can be difficult, requiring advanced echocardiographic skills. Additionally, circulating biomarkers (N-terminal pro-B type natriuretic peptide and cardiac troponin I) have several limitations when used for HCM screening. In previous work, we identified interleukin 18 (IL-18), insulin-like growth factor binding protein 2 (IGFBP-2), brain-type glycogen phosphorylase B (PYGB), and WNT Family Member 5 A (WNT5A) as myocardial genes that show significant differential expression between cats with HCM and healthy cats. The products of these genes are released into the circulation, and we hypothesized that IL-18, IGFBP-2, PYGB, and WNT5A serum RNA and protein concentrations differ between healthy cats, cats with subclinical HCM, and those with HCM and congestive heart failure (HCM + CHF).

Reverse transcriptase quantitative polymerase chain reaction (RTqPCR) and enzyme-linked immunosorbent assay (ELISA) were applied to evaluate gene and protein expression, respectively, in the serum of eight healthy controls, eight cats with subclinical HCM, and six cats with HCM + CHF. Serum IGFBP-2 RNA concentrations were significantly different among groups and were highest in cats with subclinical HCM. Compared to healthy controls, serum IL-18 and WNT5A gene expression were significantly higher in cats with HCM + CHF, and WNT5A was higher in cats with subclinical HCM. No differences were observed for PYGB.

These results indicate that further investigation via large scale clinical studies for IGFBP-2, WNT5A, and IL-18 may be valuable in diagnosing and staging feline HCM.

查看原文本刊更多论文

评估猫肥厚型心肌病的潜在新型生物标记物

肥厚性心肌病（HCM）是猫最常见的心肌病。诊断可能很困难，需要高级超声心动图技能。此外，循环生物标志物（N-末端前 B 型利钠肽和心肌肌钙蛋白 I）在用于 HCM 筛查时也有一些局限性。在之前的工作中，我们发现白细胞介素 18 (IL-18)、胰岛素样生长因子结合蛋白 2 (IGFBP-2)、脑型糖原磷酸化酶 B (PYGB) 和 WNT 家族成员 5 A (WNT5A) 作为心肌基因在 HCM 猫和健康猫之间有显著的表达差异。我们假设 IL-18、IGFBP-2、PYGB 和 WNT5A 血清 RNA 和蛋白质浓度在健康猫、亚临床 HCM 猫和 HCM 合并充血性心力衰竭（HCM + CHF）猫之间存在差异。应用逆转录酶定量聚合酶链反应（RTqPCR）和酶联免疫吸附试验（ELISA）分别评估了八名健康对照组、八名亚临床 HCM 患者和六名 HCM + CHF 患者血清中的基因和蛋白表达。血清 IGFBP-2 RNA 浓度在各组间存在显著差异，亚临床 HCM 猫的浓度最高。与健康对照组相比，HCM + CHF 猫的血清 IL-18 和 WNT5A 基因表达明显升高，亚临床 HCM 猫的 WNT5A 基因表达升高。这些结果表明，通过大规模临床研究对 IGFBP-2、WNT5A 和 IL-18 进行进一步调查可能对猫 HCM 的诊断和分期很有价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Research in veterinary science 农林科学-兽医学

CiteScore

4.40

自引率

4.20%

发文量

312

审稿时长

75 days

期刊介绍： Research in Veterinary Science is an International multi-disciplinary journal publishing original articles, reviews and short communications of a high scientific and ethical standard in all aspects of veterinary and biomedical research. The primary aim of the journal is to inform veterinary and biomedical scientists of significant advances in veterinary and related research through prompt publication and dissemination. Secondly, the journal aims to provide a general multi-disciplinary forum for discussion and debate of news and issues concerning veterinary science. Thirdly, to promote the dissemination of knowledge to a broader range of professions, globally. High quality papers on all species of animals are considered, particularly those considered to be of high scientific importance and originality, and with interdisciplinary interest. The journal encourages papers providing results that have clear implications for understanding disease pathogenesis and for the development of control measures or treatments, as well as those dealing with a comparative biomedical approach, which represents a substantial improvement to animal and human health. Studies without a robust scientific hypothesis or that are preliminary, or of weak originality, as well as negative results, are not appropriate for the journal. Furthermore, observational approaches, case studies or field reports lacking an advancement in general knowledge do not fall within the scope of the journal.